Comparative safety and efficacy study of two atrophic rhinitis vaccines in gilts

Strona główna Wiedza Comparative safety and efficacy study of two atrophic rhinitis vaccines in gilts

Comparative safety and efficacy study of two atrophic rhinitis vaccines in gilts

The aim of this study was to evaluate and compare the efficacy and safety of two commercially available vaccines for the prevention of atrophic rhinitis (AR) in swine by comparing the serological response and the body temperature increase after vaccination. RHINISENG® is a vaccine for the prevention of progressive and non-progressive AR in swine, which contains HIPRAMUNE® Gd as an adjuvant. The other commercial vaccine used in this study is based on dl-α-tocopherol and is only indicated against progressive AR.

O tym artykule

Opublikowano w

ESPHM Congress, 2016

Autorzy

Acal, L.; Montané, J.; Camprodon, A.; Pedrazuela, R.; March, R.

Streszczenie

The results obtained by RHINISENG® (group 1) showed a lower body temperature increase and a higher and more homogeneous humoral immune response against PMT after vaccination than the results obtained by its competitor (group 2) under field conditions.

Powiązane usługi

Powiązane produkty

Udostępnij na